{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T21:41:07Z","timestamp":1776894067235,"version":"3.51.2"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Sanofi and Regeneron Pharmaceuticals, Inc"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jacl.2020.01.001","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T17:05:12Z","timestamp":1578935112000},"page":"88-97.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and safety of alirocumab in statin-intolerant patients over 3\u00a0years: open-label treatment period of the ODYSSEY ALTERNATIVE trial"],"prefix":"10.1016","volume":"14","author":[{"given":"Patrick M.","family":"Moriarty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Guyton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franklin J.","family":"Zieve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie T.","family":"Baccara-Dinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9067-6439","authenticated-orcid":false,"given":"Stephen","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shazia","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garen","family":"Manvelian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2020.01.001_bib1","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jacl.2017.05.001","article-title":"Update on the use of PCSK9 inhibitors in adults: recommendations from an Expert Panel of the National Lipid Association","volume":"11","author":"Orringer","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2020.01.001_bib2","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2020.01.001_bib3","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.01.001_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.01.001_bib5","doi-asserted-by":"crossref","first-page":"e13032","DOI":"10.1111\/ijcp.13032","article-title":"Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres","volume":"71","author":"Kohli","year":"2017","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacl.2020.01.001_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2017.11.027","article-title":"PCSK9 inhibitors in clinical practice: Delivering on the promise?","volume":"270","author":"Stoekenbroek","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2020.01.001_bib7","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacl.2018.01.013","article-title":"Alirocumab in high-risk patients: Observations from the open-label expanded use program","volume":"12","author":"Glueck","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2020.01.001_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIRCRESAHA.118.314191","article-title":"Application of PCSK9 inhibitors in practice","volume":"124","author":"Kaufman","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2020.01.001_bib9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2020.01.001_bib10","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2020.01.001_bib11","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2020.01.001_bib12","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2020.01.001_bib13","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMc1616623","article-title":"Antidrug antibodies in patients treated with alirocumab","volume":"376","author":"Roth","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.01.001_bib15","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2020.01.001_bib16","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijcard.2016.08.273","article-title":"Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials","volume":"223","author":"Farnier","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2020.01.001_bib17","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.amjcard.2016.08.072","article-title":"Safety of alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials","volume":"118","author":"Jones","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2020.01.001_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2018.08.036","article-title":"Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program","volume":"278","author":"Farnier","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2020.01.001_bib19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2020.01.001_bib20","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420300015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420300015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:34:36Z","timestamp":1761831276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287420300015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1933287420300015"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2020.01.001","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of alirocumab in statin-intolerant patients over 3\u00a0years: open-label treatment period of the ODYSSEY ALTERNATIVE trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2020.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}